[1] |
王蔚. 成人骨髓增生异常综合征和再生障碍性盆血的发病率和预后研究[D]. 上海: 复旦大学, 2010.
|
|
WANG W. A Study on incidence,survival rate and prognostic factors of Myelodysplastic syndrome and aplastic anemia in adults[D]. Shanghai: Fudan University, 2010
|
[2] |
宋陆茜, 常春康. 2023年美国国立综合癌症网络(NCCN)《骨髓增生异常综合征临床实践指南》(第1版)解读[J]. 诊断学理论与实践, 2023, 22(2):116-120.
|
|
SONG L Q, CHANG C K. Interpretation of clinical prae-tice guidelines for myelodysplastie syndrome (version 1, 2023) of National Comprehensive Cancer Nerwork(NCCN)[J]. J Diagn Concepts Pract, 2023, 22(2):116-120.
|
[3] |
姚玉前, 戴碧涛. 骨髓增生异常综合征流行病学的研究进展[J]. 儿科药学杂志, 2012, 18(4):4.
|
|
YAO Y Q, DAI B T. Epidemiological Progress of Myelodysplastic Syndrome[J]. J Pediatr Pharm, 2012, 18(4):4.
|
[4] |
肖志坚. 骨髓增生异常综合征的诊断[J]. 诊断学理论与实践, 2016, 15(6):545-549.
|
|
XIAO Z J. Diagnosis of myelodysplastic syndrome[J]. J Diagn Concept & Pract, 2016, 15(6):545-549.
|
[5] |
KHOURY J D, SOLARY E, ABLA O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms[J]. Leukemia, 2022, 36(7):1703-1719.
doi: 10.1038/s41375-022-01613-1
|
[6] |
ARBER D A, ORAZI A, HASSERJIAN R P, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data[J]. Blood, 2022, 140(11):1200-1228.
|
[7] |
GREENBERG P L, TUECHLER H, SCHANZ J, et al. Revised international prognostic scoring system for myelodysplastic syndromes[J]. Blood, 2012, 120(12):2454-2465.
doi: 10.1182/blood-2012-03-420489
pmid: 22740453
|
[8] |
BERNARD E, NANNYA Y, HASSERJIAN R P, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes[J]. Nat Med, 2020, 26(10):1549-1556.
doi: 10.1038/s41591-020-1008-z
|
[9] |
HAASE D, STEVENSON K E, NEUBERG D, et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups[J]. Leukemia, 2019, 33(7):1747-1758.
doi: 10.1038/s41375-018-0351-2
pmid: 30635634
|
[10] |
BERNARD E, TUECHLER H, GREENBERG P L, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes[J]. NEJM Evid, 2022, 1(7):EVIDoa2200008.
|
[11] |
JAIN A G, ZHANG L, BENNETT J M, et al. Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update[J]. Ann Lab Med, 2022, 42(3):299-305.
doi: 10.3343/alm.2022.42.3.299
pmid: 34907099
|
[12] |
GREENBERG P L, STONE R M, AL-KALI A, et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2017, 15(1):60-87.
doi: 10.6004/jnccn.2017.0007
URL
|
[13] |
BEJAR R. Prognostic models in myelodysplastic syndromes[J]. Hematology Am Soc Hematol Educ Program, 2013, 2013:504-510.
doi: 10.1182/asheducation-2013.1.504
pmid: 24319225
|
[14] |
GREENBERG P, COX C, LEBEAU M M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes[J]. Blood, 1997, 89(6):2079-2088.
pmid: 9058730
|
[15] |
MALCOVATI L, DELLA PORTA M G, STRUPP C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)[J]. Haematologica, 2011, 96(10):1433-1440.
doi: 10.3324/haematol.2011.044602
pmid: 21659359
|
[16] |
ALESSANDRINO E P, DELLA PORTA M G, BACIGALUPO A, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)[J]. Blood, 2008, 112(3):895-902.
doi: 10.1182/blood-2008-03-143735
pmid: 18497321
|
[17] |
PARK M J, KIM H J, KIM S H, et al. Is International Prognostic Scoring System (IPSS) still standard in predic-ting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS[J]. Eur J Haematol, 2008, 81(5):364-373.
doi: 10.1111/ejh.2008.81.issue-5
URL
|
[18] |
ZEIDAN A M, KOMROKJI R S. There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes[J]. Curr Hematol Malig Rep, 2013, 8(4):351-360.
doi: 10.1007/s11899-013-0172-3
URL
|
[19] |
VOSO M T, FENU S, LATAGLIATA R, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database[J]. J Clin Oncol, 2013, 31(21):2671-2677.
doi: 10.1200/JCO.2012.48.0764
pmid: 23796988
|
[20] |
GANGAT N, PATNAIK M M, TEFFERI A. Myelodysplastic syndromes: Contemporary review and how we treat[J]. Am J Hematol, 2016, 91(1):76-89.
doi: 10.1002/ajh.24253
pmid: 26769228
|
[21] |
OK C Y, HASSERJIAN R P, FOX P S, et al. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia[J]. Leukemia, 2014, 28(1):185-189.
doi: 10.1038/leu.2013.191
pmid: 23787392
|
[22] |
MALCOVATI L, KARIMI M, PAPAEMMANUIL E, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts[J]. Blood, 2015, 126:233-241. DOI: 10.1182/blood-2015-03-633537.
pmid: 25957392
|
[23] |
MALCOVATI L, STEVENSON K, PAPAEMMANUIL E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS[J]. Blood, 2020, 136(2):157-170.
doi: 10.1182/blood.2020004850
pmid: 32347921
|
[24] |
OGAWA S. Genetics of MDS. Blood[J]. 2019; 133(10):1049-1059.
|
[25] |
GANGULY B B, KADAM N N. Mutations of myelodysplastic syndromes (MDS): An update[J]. Mutat Res Rev Mutat Res, 2016, 769:47-62.
doi: 10.1016/j.mrrev.2016.04.009
pmid: 27543316
|
[26] |
WU J, ZHANG Y, QIN T, et al. IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes[J]. Exp Hematol Oncol, 2022, 11(1):73.
doi: 10.1186/s40164-022-00328-4
|
[27] |
SAUTA E, ROBIN M, BERSANELLI M, et al. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes[J]. J Clin Oncol, 2023, 41(15):2827-2842.
doi: 10.1200/JCO.22.01784
URL
|
[28] |
MALCOVATI L, STEVENSON K, PAPAEMMANUIL E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS[J]. Blood, 2020, 136(2):157-170.
doi: 10.1182/blood.2020004850
pmid: 32347921
|
[29] |
DELHOMMEAU F, DUPONT S, DELLA VALLE V, et al. Mutation in TET2 in myeloid cancers[J]. N Engl J Med, 2009, 360(22):2289-2301.
doi: 10.1056/NEJMoa0810069
URL
|
[30] |
CIMMINO L, DOLGALEV I, WANG Y, et al. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression[J]. Cell, 2017, 170(6):1079-1095.e20.
doi: S0092-8674(17)30868-1
pmid: 28823558
|
[31] |
HUANG F, SUN J, CHEN W, et al. HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML[J]. Aging, 2020, 12(17),16759-16774
doi: 10.18632/aging.v12i17
URL
|
[32] |
FUJINO T, KITAMURA T. ASXL1 mutation in clonal hematopoiesis[J]. Exp Hematol, 2020, 83:74-84.
doi: S0301-472X(20)30002-3
pmid: 31945396
|
[33] |
FANG Y, GUO J, WU D, et al. Integration Analysis of JAK2 or RUNX1 Mutation With Bone Marrow Blast Can Improve Risk Stratification in the Patients With Lower Risk Myelodysplastic Syndrome[J]. Front Oncol, 2021, 10:610525.
doi: 10.3389/fonc.2020.610525
URL
|